East China Pharmaceuticals has reached a partnership with Excientia to accelerate the development of anti-tumor drugs through AI.

On September 9th Exscientia, an artificial intelligence (AI) drug research and development company, and East China Pharmaceuticals announced that they had established a partnership to accelerate the discovery of breakthrough innovative therapies for small molecule drugs in the field of oncology.
project between the two companies is the development of drugs for DNA injury response gene transcription control to treat patients with high mutation frequency of DNA injury repair defects, such as ovarian and breast cancer patients.
the development of small molecule anti-tumor drugs based on resources and advantages in artificial intelligence and drug research and development.
Excientia uses its advanced Centaur ChemistTM AI platform for automated drug development guidance to design new molecules for specific targets, and East China Pharmaceuticals uses research and development resources and management capabilities to rapidly synthesize and test for new rounds of compounds in AI systems.
East China Pharmaceuticals is one of the top 10 listed pharmaceutical companies (SZ.000963) in Forbes 2020, with more than 10,000 employees and annual sales of more than $4 billion.
cooperation will accelerate the strategic transformation of east China Pharmaceutical Innovation Drugs and help Excientia promote AI design innovative drugs globally.
is understood to be the world's leading artificial intelligence (AI)-driven drug discovery company, which was established in the UK in 2012.
By combining the power of artificial intelligence with experienced drug scientists, Excientia's innovative Centaur Chemist™ platform enables breakthrough drug development efficiency, with new compounds automatically designed by AI systems and prioritized for synthesis, rapidly advancing compounds to the candidate compound standards required for clinical development.
.